Recursion Pharmaceuticals (RXRX) Other Non-Current Assets (2020 - 2026)

Recursion Pharmaceuticals has reported Other Non-Current Assets for 7 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 64.84% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 64.84% YoY), and the FY2025 full-year result was $12.8 million, up 44.52% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $5.2 million, down from $12.8 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $14.8 million in Q1 2025, with the low at $110000.0 in Q2 2023.
• Historically, Other Non-Current Assets has averaged $6.7 million across 5 years, with a median of $8.0 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 23197.14% — and 2023, when it sank 98.68%.
• Recursion Pharmaceuticals' Other Non-Current Assets stood at $8.2 million in 2022, then declined by 18.7% to $6.6 million in 2023, then surged by 33.13% to $8.8 million in 2024, then jumped by 44.52% to $12.8 million in 2025, then tumbled by 59.26% to $5.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $5.2 million (Q1 2026), $12.8 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.